ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that several ImmunoGen poster presentations will be made at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held in Berlin, Germany, November 16-19, 2010.
“Antibody-maytansinoid conjugates targeting Folate Receptor 1 for cancer therapy”
"Our presentations at this Symposium reflect our expanding product pipeline and technology portfolio," commented John Lambert, Ph.D., Executive Vice President and Chief Scientific Officer. "We'll be reporting additional clinical data for our IMGN388 compound as well as preclinical data generated in our development of IMGN853, a TAP compound that targets Folate Receptor 1. We'll also be presenting data on one of our linkers that enhances the effectiveness of TAP compounds against cancers with multi-drug resistance."
On Nov. 17 from 12-2:20 pm CET/6:00-8:20 am ET:
- "Antibody-maytansinoid conjugates targeting Folate Receptor 1 for cancer therapy" (Abstract #236, Poster board #193).
- "Negatively-charged sulfonate group in linker improves potency of antibody-maytansinoid conjugates against multidrug-resistant cancer cells" (Abstract #235, Poster board #192).
On Nov. 19 from 8-9:30 am CET/2:00-3:30 am ET:
- "A Phase I Study of IMGN388, an antibody drug conjugate targeting av Integrin, in patients with solid tumors" (Abstract #472, Poster board #008).
Data on TAP compounds in development by ImmunoGen partners also will be presented at this conference.
Global study reveals shifting trends in ovarian cancer incidence by subtype and region